---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000092"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:29:49.356633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510

## Summary
- Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.
- First patient dosed in Phase 1 trial of AXN-2510/IMM2510 monotherapy in advanced solid tumors in October 2025.
- R&D expenses $9.1M in Q3 2025 vs $0.6M in Q3 2024; reflecting increased clinical activity.
- Net loss per share (GAAP) $2.01 in Q3 2025 vs $3.54 in Q3 2024; non-GAAP net loss $1.75 vs $2.55.

## SEC filing metadata
- accession: 0001789769-25-000092
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/0001789769-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/til-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000092
- JSON: https://secwatch.observer/filing/0001789769-25-000092.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.